RT Book, Section
A1 Atherton, John C.
A1 Blaser, Martin J.
A2 Jameson, J. Larry
A2 Fauci, Anthony S.
A2 Kasper, Dennis L.
A2 Hauser, Stephen L.
A2 Longo, Dan L.
A2 Loscalzo, Joseph
SR Print(0)
ID 1155967324
T1 Helicobacter pylori Infections
T2 Harrison's Principles of Internal Medicine, 20e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781259644016
LK accessmedicine.mhmedical.com/content.aspx?aid=1155967324
RD 2024/04/25
AB Helicobacter  pylori  colonizes  the  stomach  in  ~50%  of  the  world’s  human  population,  essentially  for  life  unless  eradicated  by  antibiotic  treatment.  Colonization  with  this  organism  is  the  main  risk  factor  for  peptic  ulceration  (Chap.  317)  as  well  as  for  gastric  adenocarcinoma  and  gastric  mucosa-associated  lymphoid  tissue  (MALT)  lymphoma  (Chap.  76).  Treatment  for  H.  pylori  has  revolutionized  the  management  of  peptic  ulcer  disease,  providing  a  permanent  cure  in  most  cases.  Such  treatment  also  represents  first-line  therapy  for  patients  with  low-grade  gastric  MALT  lymphoma.  Treatment  of  H.  pylori  is  of  no  benefit  in  the  treatment  of  gastric  adenocarcinoma,  but  prevention  of  H.  pylori  colonization  or  eradicative  treatment  could  potentially  prevent  gastric  malignancy  and  peptic  ulceration.  In  contrast,  increasing  evidence  indicates  that  lifelong  H.  pylori  colonization  may  offer  some  protection  against  complications  of  gastroesophageal  reflux  disease  (GERD),  including  esophageal  adenocarcinoma.  Recent  research  has  focused  on  whether  H.  pylori  colonization  is  also  a  risk  factor  for  some  extragastric  diseases  and  whether  it  is  protective  against  some  recently  emergent  medical  problems,  such  as  childhood-onset  asthma  and  other  allergic  and  metabolic  conditions.